Terms: = Bone cancer AND FES, FPS, 2242, ENSG00000182511, P07332 AND Treatment
19 results:
1. High-performance pyrite nano-catalyst driven photothermal/chemodynamic synergistic therapy for Osteosarcoma.
Li M; Wang M; Huang J; Tang S; Yang J; Xu Z; Xu G; Chen X; Liu J; Yang C
J Nanobiotechnology; 2024 Apr; 22(1):141. PubMed ID: 38561739
[TBL] [Abstract] [Full Text] [Related]
2. Can 18F-fes PET Improve the Evaluation of 18F-FDG PET in Patients With Metastatic Invasive Lobular Carcinoma?
Liu C; Ma G; Xu X; Song S; Yang Z
Clin Nucl Med; 2024 Apr; 49(4):301-307. PubMed ID: 38427956
[TBL] [Abstract] [Full Text] [Related]
3. Women's Health Update: Growing Role of PET for Patients with Breast cancer.
Ulaner GA; Vaz SC
Semin Nucl Med; 2024 Mar; 54(2):247-255. PubMed ID: 38365547
[TBL] [Abstract] [Full Text] [Related]
4. Quarter-Century Transformation of Oncology: Positron Emission Tomography for Patients with Breast cancer.
Ulaner GA; Vaz SC; Groheux D
PET Clin; 2024 Apr; 19(2):147-162. PubMed ID: 38177052
[TBL] [Abstract] [Full Text] [Related]
5. [Evaluation of the Short-Term Efficacy and Safety of Orelabrutinib Combined with High-Dose Methotrexate in the First-line treatment of Elderly Patients with High Risk Primary Central Nervous System Lymphoma].
Xie Y; Qu S; Liao LS; Zheng ZH; Lin Y; Chen WM; Chen BY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1714-1719. PubMed ID: 38071050
[TBL] [Abstract] [Full Text] [Related]
6. 16α-18F-fluoro-17β-Fluoroestradiol (fes): Clinical Applications for Patients With Breast cancer.
Ulaner GA
Semin Nucl Med; 2022 Sep; 52(5):574-583. PubMed ID: 35379454
[TBL] [Abstract] [Full Text] [Related]
7. Real-time markerless tumour tracking with patient-specific deep learning using a personalised data generation strategy: proof of concept by phantom study.
Takahashi W; Oshikawa S; Mori S
Br J Radiol; 2020 May; 93(1109):20190420. PubMed ID: 32101456
[TBL] [Abstract] [Full Text] [Related]
8. treatment plan quality and delivery accuracy assessments on 3 IMRT delivery methods of stereotactic body radiotherapy for spine tumors.
Huang L; Djemil T; Zhuang T; Andrews M; Chao ST; Suh JH; Xia P
Med Dosim; 2019 Spring; 44(1):11-14. PubMed ID: 29429794
[TBL] [Abstract] [Full Text] [Related]
9. Dual inhibition of fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
Weir MC; Hellwig S; Tan L; Liu Y; Gray NS; Smithgall TE
PLoS One; 2017; 12(7):e0181178. PubMed ID: 28727840
[TBL] [Abstract] [Full Text] [Related]
10. An autopsy case of non-traumatic fat embolism syndrome.
Sakashita M; Sakashita S; Sakata A; Uesugi N; Ishige K; Hyodo I; Noguchi M
Pathol Int; 2017 Sep; 67(9):477-482. PubMed ID: 28667706
[TBL] [Abstract] [Full Text] [Related]
11. Kinase Activity in Recurring Primary Skull Base Chordomas and Chondrosarcomas: Identification of Novel Pathways of Oncogenesis and Potential Drug Targets.
Tatman PD; Osbun J; Yakkioui Y; Kaur S; Parada C; Busald T; Born D; Ahmad O; Zhang J; Ferreira M
World Neurosurg; 2017 Nov; 107():75-81. PubMed ID: 28647652
[TBL] [Abstract] [Full Text] [Related]
12. Follow-up after treatment for breast cancer: Practical guide to survivorship care for family physicians.
Sisler J; Chaput G; Sussman J; Ozokwelu E
Can Fam Physician; 2016 Oct; 62(10):805-811. PubMed ID: 27737976
[TBL] [Abstract] [Full Text] [Related]
13. Positron emission tomography of tumour [(18)F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy.
van Kruchten M; Glaudemans AWJM; de Vries EFJ; Schröder CP; de Vries EGE; Hospers GAP
Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1674-1681. PubMed ID: 26091705
[TBL] [Abstract] [Full Text] [Related]
14. Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.
Gemignani ML; Patil S; Seshan VE; Sampson M; Humm JL; Lewis JS; Brogi E; Larson SM; Morrow M; Pandit-Taskar N
J Nucl Med; 2013 Oct; 54(10):1697-702. PubMed ID: 23970364
[TBL] [Abstract] [Full Text] [Related]
15. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.
Linden HM; Kurland BF; Peterson LM; Schubert EK; Gralow JR; Specht JM; Ellis GK; Lawton TJ; Livingston RB; Petra PH; Link JM; Krohn KA; Mankoff DA
Clin Cancer Res; 2011 Jul; 17(14):4799-805. PubMed ID: 21750198
[TBL] [Abstract] [Full Text] [Related]
16. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.
Linden HM; Stekhova SA; Link JM; Gralow JR; Livingston RB; Ellis GK; Petra PH; Peterson LM; Schubert EK; Dunnwald LK; Krohn KA; Mankoff DA
J Clin Oncol; 2006 Jun; 24(18):2793-9. PubMed ID: 16682724
[TBL] [Abstract] [Full Text] [Related]
17. Chronic myelogenous leukemia: molecular and cellular aspects.
Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
[TBL] [Abstract] [Full Text] [Related]
18. [Clinicopathological study of gastric cancer with bone metastasis].
Nishidoi H; Koga S
Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 2):1717-22. PubMed ID: 3592711
[TBL] [Abstract] [Full Text] [Related]
19. [Phase II study of the water-soluble nitrosourea compound ACNU in advanced colorectal carcinomas].
Fiebig HH; Wellens W; Peukert M; Henss H; Arnold H; Westerhausen M; Löhr GW
Onkologie; 1984 Dec; 7(6):370-7. PubMed ID: 6396565
[TBL] [Abstract] [Full Text] [Related]
